DELAY in the easing of Covid-19 restrictions and harsh summer weather led to a slowdown in sales at Asos last month, The Times reported.
The online retailer registered a 27 per cent increase in the group’s revenue to £1.29 billion in the four months to June 30, backed by surge in sales.
The business hailed it as “strong, against a backdrop of continued restrictions on consumers, volatile demand and increased global supply chain pressures”.
Asos, which is focused on young shoppers, said that sales in the past three weeks were muted as young people’s hopes of going out in groups on June 21 dashed following the delay in lifting restrictions.
This resulted in reduced sale of going-out dresses.
Besides, the rainy summer in the UK dampened demand for summer outfits.
In the wake of global uncertainty due to the pandemic, the company expected growth in the fourth quarter to be comparable with last year and full-year adjusted pre-tax profits to be in line with expectations.
This adjustment would strip out £6 million of interest charges related to its £500m bond issue in April and costs associated with its recent £295m Topshop acquisitions.
Asos disclosed underlying sales figures for the last quarter, which showed a slower rate of growth than its reported figures as its level of customer returns was lower than it estimated.
As a result, its fourth-quarter sales in 2020 were higher at £1.1bn than the £1.01bn that it reported last year. Its underlying growth during this quarter was 17 per cent, or 21 per cent at constant currency, rather than the 27 per cent reported growth.
Founded in 2000 by Nick Robertson, Asos is currently valued at £4.68bn, but is still listed on London’s junior Aim market.
“Although mindful of the continued impacts of the pandemic on our customers in the short term, we believe that the structure of the global ecommerce fashion market has changed for ever, which will drive an increase in online fashion sales over the long term,” said Nick Beighton, Asos chief executive.
“We’re excited about the size of the prize ahead of us and the opportunity of delivering on our ambition of being the number one destination for fashion-loving twentysomethings,” he said.
Earlier this week, the company announced to sell Topshop and selected Asos ranges in Nordstrom shops in the US.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.